John Spurzem
Pulmonary Disease · San Rafael, CANPI 1467489930
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 291 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,055 and has fallen 63.6% since, to $748 in 2023.
Across 291 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$830
- GSK$676
- Boehringer Ingelheim$553
- AstraZeneca$458
- Pfizer$447
- United Therapeutics Corporation$346
- plus $3K from 28 others
Across 70 payments — averaging $5264.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$189K
- Vertex$180K
What the payments were for
- Food & beverage$6,11999%
- Gifts$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 38 | $830 |
| GSK | 41 | $676 |
| Boehringer Ingelheim | 33 | $553 |
| AstraZeneca | 19 | $458 |
| Pfizer | 23 | $447 |
| United Therapeutics Corporation | 14 | $346 |
| Merck | 15 | $344 |
| Insmed, Inc. | 12 | $309 |
| Mallinckrodt Hospital Products Inc. | 9 | $217 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $163 |
| Gilead | 11 | $158 |
| Sunovion Pharmaceuticals Inc. | 7 | $150 |
| Intuitive Surgical | 2 | $145 |
| Bayer | 8 | $145 |
| Chiesi USA, Inc. | 3 | $135 |
| Amgen | 1 | $125 |
| AbbVie | 7 | $116 |
| Astellas Pharma US Inc | 5 | $104 |
| Mallinckrodt Enterprises LLC | 4 | $88 |
| Sanofi | 4 | $85 |
| Regeneron Healthcare Solutions, Inc. | 3 | $84 |
| Philips North America LLC | 3 | $82 |
| Genentech USA, Inc. | 5 | $73 |
| Electromed, Inc. | 1 | $63 |
| Grifols USA, LLC | 4 | $59 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $42 |
| La Jolla Pharmaceutical Company | 3 | $39 |
| Vapotherm Inc | 2 | $36 |
| Mylan Specialty L.p. | 2 | $34 |
| Circassia Inc. | 1 | $20 |
| Inari Medical, Inc. | 1 | $19 |
| Portola Pharmaceuticals, LLC | 1 | $18 |
| Novartis | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,190 in reported general payments places this provider in the 70th percentile of 1,261 pulmonary disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $730 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in San Rafael
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.